Synergy between the non-classical thymidylate synthase inhibitor AG337 (Thymitaq®) and cisplatin in human colon and ovarian cancer cells

Anti-Cancer Drugs

Volumn 7, Issue 7, 1996, Pages 752-757

  Raymond, Eric ^a,b,c   Djelloul, Siham ^a   Buquet Fagot, Christine ^a   Mester, Jan ^a   Gespach, Christian ^a  

^a HÔPITAL SAINT ANTOINE   (France)

^b HÔPITAL PAUL BROUSSE   (France)

^c CTRC Institute for Drug Development   (United States)

Author keywords

Antimetabolites; Combination chemotherapy; Platinum; Quinazoline antifolate

Indexed keywords

CISPLATIN; FLUOROURACIL; NOLATREXED; THYMIDYLATE SYNTHASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; DRUG RESISTANCE; GENE AMPLIFICATION; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL;

EID: 0029860017     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199609000-00006     Document Type: Article

References (17)

1. Grem LG. Fluorinated pyrimidines. In: Chabner BA, Collins JM, eds. Cancer chemotherapy: principles and practice. Philadelphia: JB Lippincott 1990: 180-224.
2. Ashele C, Sobrero A, Faderan MA, Bertino JR. Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant close schedules. Cancer Res 1992; 52: 1855-64.
3. Johnston PG, Fisher ER, Rockette HE, et al. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 1994; 12: 2640-7.
4. Nord LD, Martin DS. Enhancement of thymidylate synthase inhibition Curr Opin Oncol 1993; 5: 1017-22.
5. Jackson RC, Johnston AL, Shetty BV, Varney MD, Webber S, Webber SE. Molecular design of thymidylate synthase inhibitors. Proc Am Ass Cancer Res 1993; 34: 566-7.
6. Jackson RC, Boritzki TK, Johnston AL, et al. Design and development of lipophilic inhibitors of thymidylate synthase. Proc Am Ass Cancer Res 1992; 33: A592.
7. Calvette JA, Balmanno K, Taylor GA, et al. Pre-clinical and clinical studies of prolonged administration of the novel thymidylate synthase inhibitor, AG337. 8th NCI-EORTC symposium on new drugs in cancer therapy. Ann Oncol 1994; 5 (suppl 5): A248.
8. Creaven PJ, Pendyala L, Meropol NJ, Wu EY, Clendeninn NJ. Phase I and pharmacokinetic study of 3,4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridylthio)-quinazoline dihydrochloride (thymitaq, AG337) Ann Oncol 1996; 7 (suppl 1): A292.
9. Huang H, Zhu L, Reld BR, Drobny GP, Hopkins PB. Solution structure of a cisplatin-induced DNA interstrand cross-link. Science 1995; 270: 1842-4.
10. Schabel FM, Trader MW, Laster WR, Corbett TH, Griswold DP. Cis-dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat Rep 1979; 63: 1459-73.
11. Lesuffleur T, Komowski A, Augeron C, et al. Increased growth adaptability to 5-fluorouracil and methotrexate of HT29 subpopulations selected for their commitment to differentiation. Int J Cancer 1992; 49: 731-7.
12. Andrews PA, Murphy MP Howell SB. Differential potentiation of alkylating and platinating agent toxicity in human ovarian carcinoma cells by gluthathione depletion. Cancer Res 1985; 45: 6250-3.
13. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enz Regul 1984; 22: 27-55.
14. Tong Y, Banerjee D, Bertino JR. Mechanisms of resistance to the thymidylate synthase inhibitor AG337 in human sarcoma HT1080 cells after exposure to ethylmethanesulfonate (EMS). Proc Am Ass Cancer Res 1996; 27: A2621.
15. Andrews PA, Albright KD. Mitochondrial defects in cis-diaminedichloroplatinum(II)-resistant human ovarian carcinoma cells. Cancer Res 1992; 52: 1895-901.
16. Zinkewich-Péotti K, Andrews PA. Loss of cis-diamminedichloroplatinum(II) resistance in human ovarian carcinoma cells selected for rhodamine 123 resistance. Cancer Res 1992; 52: 1902-6.
17. Scanlon KJ, Kashani-Sabet M, Tone T, Funato T. Cisplatin resistance in human cancers. Pharmac Ther 1991; 52: 385-406.